Loading
A phase 2 trial of toripalimab, gemcitabine, oxaliplatin and surufatinib in gallbladder cancer and other biliary tract cancers, run by Fujian Cancer Hospital, not yet recruiting.
A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer. is a phase 2 interventional study registered as NCT06654947 by Fujian Cancer Hospital, with a registry enrolment figure of 23 participants, started 2025-01 and due to reach its primary completion in 2026-12. Interventions recorded: Surufatinib+Toripalimab+GEMOX. Conditions listed: Biliary Tract Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Surufatinib, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.
Shares Toripalimab, Oxaliplatin, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Gemcitabine and the tag gallbladder-deep-dive.
Shares Oxaliplatin, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.
Shares Toripalimab, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Shares Oxaliplatin, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.
Shares Surufatinib, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Shares Toripalimab, Oxaliplatin, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
Shares Oxaliplatin, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/